[Matt]

Questions Regarding Carfilzomib, pomalidomide and Perifosine

by Matt on Tue May 24, 2011 6:32 pm

This question is for Drs. Siegel and Vesole.

In April 2009 I was diagnosed with stage 3 non-secretory multiple myeloma and was treated at Hackensack. After three cycles of of Revlimid, Velcade, and Dex I achieved a complete response. I still went on to have the stem cell transplant in August of 2009. Last fall at the ASH Conference the latest data showed very high levels of response with this combo.

My question is this: do you expect that the combination of carfilzomib [Kyprolis], pomalidomide [Pomalyst] and Decadron will have similar results, especially for relapsed patients who are resistant to Velcade and Revlimid? And what role do you see for perifosine for relapsed patients?

[Dr. David Siegel]

Re: Questions Regarding Carfilzomib, pomalidomide and Perifo

by Dr. David Siegel on Thu May 26, 2011 4:17 pm

Obviously, we have not yet seen any results from the combination of Carfilzomib, pomalidomide and Decadron. Those trials are just starting. Having said that, my guess is that this will be a remarkably active combo. The question is, how well tolerated it will be. Nothing from my experience with these two drugs, used independently, (and we have a lot of experience at this point) would give me any reason to think it will not be well tolerated. So I would be very excited about its use in the pts you describe.

As for perifosine, the initial excitement has very much died down. It may turn out to be useful when used in combos but at this point I am not terribly enthusiastic. Fortunately, there are many drugs being tested or waiting to be tested for these pts.